ElevateBio

ElevateBio is an operator of a portfolio of cell and gene therapy companies intended to develop, manufacture, and commercialize life-transforming medicines.

The company creates a portfolio through partnerships with the world's innovative scientists and inventors as well as it created a centralized facility that integrates all the elements that translate cell and gene therapy R&D into commercially viable therapies quickly and efficiently, enabling patients to get medical products to treat severe diseases.

Vikas Sinha, Mitchell Finer, and David Hallal co-founded ElevateBio in Cambridge, Massachusetts in 2017.

ElevateBio, established in 2017 and headquartered in United States, North America., specializes in Early Stage Venture investments across Biotechnology, Health Care, Pharmaceutical, Manufacturing, Biopharma, Finance, Business Development, Application Performance Management, Financial Services, Venture Capital. The organization boasts a portfolio of 2 investments, with an average round size of $110.8M and 1 successful exits. Their recent investments include Gilead Sciences, Invus, EcoR1 Capital, F2 Ventures, Redmile Group. The highest investment round they participated in was $17.9B. Among their most notable exits are Gilead Sciences and Invus. Explore their portfolio in detail, see who is connected to them, and find their contact information on our platform.